Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.8672
−$0.0928 · -4.73%
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Regular session
$1.8672
−$0.0928 · -4.73%
Regular session · ET · Market data may be delayed.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Day range
Current $1.8672
52-week range
Current $1.8672
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
33
Expensive
Sentiment
31
Bearish
Risk
67
High Risk
Momentum
36
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Day range
Current $1.8672
52-week range
Current $1.8672
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 6.47M USD | 6.35M USD | 5.71M USD | — | 2.84M USD |
| Gross profit | −6.47M USD | −6.35M USD | −5.71M USD | — | −2.84M USD |
| Research and development | 41.11M USD | 50.48M USD | 47.25M USD | 37.67M USD | 26.51M USD |
| Selling, general, and administrative | 25.73M USD | 31M USD | 28.9M USD | 25.95M USD | 21.15M USD |
| Operating expenses | 60.37M USD | 75.12M USD | 70.45M USD | 63.62M USD | 47.66M USD |
| Interest income | 7.87M USD | 10.78M USD | 12.55M USD | 5.82M USD | 329K USD |
| Depreciation and amortization | 6.47M USD | 6.35M USD | 5.71M USD | 3.42M USD | 2.84M USD |
| Operating income | −66.84M USD | −81.48M USD | −76.15M USD | −63.62M USD | −50.5M USD |
| Net income | −59M USD | −70.78M USD | −63.68M USD | −57.92M USD | −50.32M USD |
Company facts updated Oct 8, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$3.50
87.45% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM2.67M0.00%78.56B USD0.19%$275.02-0.97%
Vanguard Morningstar Total Stock Market ETFVTI1.88M0.00%2.3T USD0.03%$379.63-0.37%
Vanguard Extended Market ETFVXF528.27K0.00%95.4B USD0.05%$231.46-0.87%
iShares Micro-Cap ETFIWC355.18K0.03%1.33B USD0.60%$181.07-1.25%
Vanguard Russell 2000 ETFVTWO279.15K0.00%18B USD0.06%$111.06-1.03%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM150K0.13%116.75M USD0.73%$15.77-1.25%
iShares Russell 2000 Growth ETFIWO132.66K0.00%14.25B USD0.24%$350.93-1.25%
iShares Russell 2500 ETFSMMD56.02K0.00%4.06B USD0.23%$85.11-0.86%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCVanguard Russell 2000 ETFVTWOEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMiShares Russell 2000 Growth ETFIWOiShares Russell 2500 ETFSMMDAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
